In This Article:
We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks.
The stock market bounced back from the previous day’s losses, with all major indices finishing higher as investors cheered the central bank's decision to keep interest rates unchanged.
On Wednesday afternoon, the Federal Reserve kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impacts of President Donald Trump’s tariff policies.
The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent.
Beyond the major indices, bucked a broader market optimism as investors sold off on a series of disappointing news.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) nosedived by 21.45 percent on Wednesday to end at $36.72 apiece after reporting a disappointing earnings performance in the first quarter of the year.
During the period, the company swung to a net loss of $447.5 million from a $36.1 million net income in the same period last year, despite revenues jumping by 80 percent to $744.9 million from $413.5 million year-on-year, with the increase primarily driven by a $241-million higher net product revenue from Elevidys—a gene therapy for Duchenne muscular dystrophy (DMD)—as a result of its expanded label approval in June 2024.
Looking ahead, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said it expects lower revenues for full-year 2025, at $2.3 billion to $2.6 billion versus the $2.9 billion to $3.1 billion as expected previously.
Earlier this year, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported that a young patient succumbed to acute liver failure after receiving the Sarepta Elevidys therapy. While the risk has already been flagged on the Elevidys label, acute liver injuries leading to death have not been previously reported in clinical testing or real-world use of Elevidys.
Overall SRPT ranks 2nd on our list of Wednesday's worst performers. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SRPT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.